Vermillion Q1 Revenues Down 7 Percent | GenomeWeb

This story has been updated to include comments from the company's earnings call.

NEW YORK (GenomeWeb News) – Vermillion reported after the close of the market Thursday that its first quarter revenues fell 7 percent to $305,000 from $328,000 in Q1 2013.

Vermillion posted product sales of $191,000, down 11 percent from $214,000 year over year. Those sales are based on 3,817 OVA1 ovarian cancer tests performed in Q1 versus 4,274 tests performed in the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.